×

TOPICAL FORMULATIONS AND USES THEREOF

  • US 20180133217A1
  • Filed: 04/27/2016
  • Published: 05/17/2018
  • Est. Priority Date: 05/04/2015
  • Status: Abandoned Application
First Claim
Patent Images

1. An ophthalmic formulation, comprising (a) a receptor tyrosine kinase (RTK) inhibitor, and (b) a polyoxyl lipid or fatty acid.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×